Table 1 |
|
|
Descriptive Statistics (n = 5790) |
|
|
Variable |
|
|
|
|
|
Age: mean (range) |
57.40 (21-94) |
|
|
|
|
TNM Stage: |
N (%) |
|
|
|
|
0 |
736 (12.7%) |
|
|
|
|
I |
2625 (45.3%) |
|
|
|
|
IIa |
1298 (22.4%) |
|
|
|
|
IIb |
729 (12.6%) |
|
|
|
|
IIIa |
239 (4.1%) |
|
|
|
|
IIIb |
116 (2.0%) |
|
|
|
|
IIIc |
47 (.8%) |
|
|
|
|
Estrogen receptor positive |
4268 (73.7%) |
|
|
|
|
Progesterone receptor positive |
3628 (62.7%) |
|
|
|
|
Treatment: |
N (%) |
|
|
|
|
Surgery only |
420 (7.3%) |
|
|
|
|
Surgery/radiation |
2764 (47.7%) |
|
|
|
|
Surgery/chemotherapy |
640 (11.1%) |
|
|
|
|
Surgery/radiation/chemotherapy |
1966 (34.0%) |
|
|
|
|
Anthracycline regimen |
1973 (75.7%) |
|
|
|
|
Non-anthracycline regimen |
646 (24.3%) |
|
|
|
|
Tamoxifen |
3554 (61.4%) |
|
|
|
|
Follow up years: mean (range) |
7.02 (.20, 18.15) |
|
|
|
|
Vital Status: |
N (%) |
|
|
|
|
Alive, NED* |
4741 (81.9%) |
|
|
|
|
Alive with this cancer |
123 (2.1%) |
|
|
|
|
Alive with other cancer |
62 (1.1%) |
|
|
|
|
Expired, NED |
354 (6.1%) |
|
|
|
|
Expired with this cancer |
388 (6.7%) |
|
|
|
|
Expired with other cancer |
121 (2.1%) |
|
|
|
|
Expired, treatment complications |
1 (.0%) |
|
|
|
|
*NED: no evidence of disease |
|
|
Kaplan et al. BMC Cancer 2011 11:260 doi:10.1186/1471-2407-11-260 |
|
